16:21 , Dec 22, 2016 |  BC Innovations  |  Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

C-Cure: Phase III data

Top-line data from the double-blind, European and Israeli Phase III CHART-1 trial in 271 evaluable patients with advanced, symptomatic CHF showed that a catheter injection of C-Cure missed the primary endpoint of improving a composite...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
01:43 , Jun 29, 2016 |  BC Extra  |  Clinical News

Celyad slides on Phase III heart failure miss

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said cell therapy C-Cure missed the primary endpoint in the Phase III CHART-1 study to treat ischemic heart failure. The company sank EUR 15.95 (40%) to EUR 23.52 in Europe and...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

2Q milestones

2Q milestones CompanyProductIndicationEventMilestoneAblynx N.V. (Euronext:ABLX)ALX-0171Respiratory syncytial virus (RSV) infectionPh I/IIa data2Q16Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)Nuplazid pimavanserinParkinson's disease psychosis (PDP)PDUFA date5/1/16Acucela Inc. (Tokyo:4589) / Otsuka Pharmaceutical Co. Ltd.EmixustatGeographic atrophy associated with dry age-related macular degeneration (AMD)Ph IIb/III data2Q16Advaxis...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Celyad, Medisun International deal

Celyad granted Medisun rights to commercialize C-Cure in Taiwan and China, including Hong Kong and Macau. Under the 15-year deal, Celyad is eligible for royalties of 10-30% on revenues and for profit sharing on...
07:00 , Jul 20, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg7/17 clsCelgene Corp. (NASDAQ:CELG)BMO Capital MarketsJim BirchenoughPrice targetOutperform13%$134.52 Deutsche BankRobyn KarnauskasPrice targetBuyBirchenough raised his target to $191 from $163 after Celgene announced it will acquire Receptos Inc. (NASDAQ:RCPT)...
01:00 , Jun 20, 2015 |  BC Extra  |  Financial News

Celyad shares fall after U.S. listing

Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) dropped $13.99 (20%) to $54.57 in its first day of trading on NASDAQ Friday after it raised $100.1 million through the sale of ADSs and a private placement of ordinary shares....
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

C-Cure: Phase III ongoing

An independent DSMB recommended continuation of the double-blind, sham-controlled, European and Israeli Phase III CHART-1 trial evaluating a catheter injection of C-Cure based on a review of safety and efficacy data after all 240 advanced...